Last reviewed · How we verify
PARP Inhibitor BGB-290
PARP Inhibitor BGB-290 is a Small molecule drug developed by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It is currently in Phase 1 development. Also known as: BGB-290, PARP, Inhibitor BGB-290, BGB-290, Pamiparib.
BGB-290, also known as pamiparib, is a small molecule inhibitor of the Poly [ADP-ribose] polymerase 1 (PARP1) enzyme. It is being studied in clinical trials for various conditions, including solid tumors, metastatic castration-resistant prostate cancer, and non-small-cell lung cancer.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PARP Inhibitor BGB-290 |
|---|---|
| Also known as | BGB-290, PARP, Inhibitor BGB-290, BGB-290, Pamiparib |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Lymphocyte count decreased
- Neutrophil count decreased
- White blood cell decreased
- Gastroesophageal Acid Reflux
- anemia
- Nausea
- Hypophosphatemia
- Platelet count decreased
- Weight loss
- Alanine aminotransferase increase
- Anorexia
Key clinical trials
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (PHASE3)
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PHASE1)
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (PHASE1)
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (PHASE1)
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma (PHASE1, PHASE2)
- Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PARP Inhibitor BGB-290 CI brief — competitive landscape report
- PARP Inhibitor BGB-290 updates RSS · CI watch RSS
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins portfolio CI
Frequently asked questions about PARP Inhibitor BGB-290
What is PARP Inhibitor BGB-290?
Who makes PARP Inhibitor BGB-290?
Is PARP Inhibitor BGB-290 also known as anything else?
What development phase is PARP Inhibitor BGB-290 in?
What are the side effects of PARP Inhibitor BGB-290?
Related
- Manufacturer: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full pipeline
- Also known as: BGB-290, PARP, Inhibitor BGB-290, BGB-290, Pamiparib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing